We have observed
3 EP applications
Andrew John Williams
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after March 19, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER
PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291
COMBINATION OF EGFR INHIBITOR AND MEK INHIBITOR FOR USE IN THE TREATMENT OF NRAS MUTATED CANCER